The Food and Drug Administration has granted Fast Track designation to SAR402663 for the treatment of neovascular AMD.

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

The amplitude of retinal thickness fluctuations in the early months of anti-VEGF treatment have no effect on later functional outcomes.

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals ...

D Molecular Therapeutics (FDMT) offers attractive growth potential with strong cash reserves and promising late-stage gene ...

In a new study, Picture Health's QVT score identified responders and non-responders to immunotherapy and chemoimmunotherapy.

CStone Pharmaceuticals ( ($HK:2616) ) has provided an update. CStone Pharmaceuticals announced the enrollment of the first patient in Australia ...

Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), ...

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and ...

Capsida Biotherapeutics has suspended a recently begun clinical trial of an experimental gene therapy after the first participant in the study died following treatment. Capsida disclosed the death in ...

The therapy is expected to block abnormal blood vessel growth, limit vascular leakage, and reduce retina damage. The Food and Drug Administration (FDA) has granted Fast Track designation to SAR402663 ...

Opponents of reunification therapy say it can psychologically harm children, while supporters say it’s unnatural for children to reject parents. Tiffanie O'Brien, right, and her daughter, Abbey, in ...